| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 14 | 2026 | 305 | 2.480 |
Why?
|
| Mycobacterium tuberculosis | 16 | 2026 | 418 | 2.420 |
Why?
|
| Metformin | 5 | 2020 | 75 | 2.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 730 | 1.210 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 225 | 1.180 |
Why?
|
| Antitubercular Agents | 4 | 2021 | 82 | 0.760 |
Why?
|
| Host-Pathogen Interactions | 4 | 2022 | 285 | 0.650 |
Why?
|
| Drug Discovery | 1 | 2020 | 95 | 0.620 |
Why?
|
| Macrophages | 6 | 2026 | 1050 | 0.570 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 24 | 0.570 |
Why?
|
| NAD | 1 | 2019 | 53 | 0.570 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 667 | 0.540 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 27 | 0.540 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2026 | 120 | 0.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 214 | 0.510 |
Why?
|
| BCG Vaccine | 2 | 2020 | 56 | 0.510 |
Why?
|
| Inflammation | 3 | 2019 | 1191 | 0.510 |
Why?
|
| Protein Kinases | 1 | 2017 | 152 | 0.510 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 699 | 0.480 |
Why?
|
| Energy Metabolism | 2 | 2019 | 394 | 0.470 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 1007 | 0.420 |
Why?
|
| Major Histocompatibility Complex | 1 | 2013 | 85 | 0.390 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 179 | 0.380 |
Why?
|
| Communicable Diseases | 1 | 2013 | 88 | 0.380 |
Why?
|
| Humans | 32 | 2026 | 64913 | 0.320 |
Why?
|
| Granuloma | 2 | 2025 | 43 | 0.320 |
Why?
|
| Animals | 18 | 2026 | 21340 | 0.320 |
Why?
|
| Granulocytes | 2 | 2026 | 73 | 0.280 |
Why?
|
| Bacteria | 2 | 2024 | 336 | 0.260 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2022 | 241 | 0.260 |
Why?
|
| Mice | 10 | 2026 | 11113 | 0.250 |
Why?
|
| Autophagy | 2 | 2026 | 233 | 0.250 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2026 | 5 | 0.240 |
Why?
|
| Mycobacterium abscessus | 1 | 2025 | 4 | 0.240 |
Why?
|
| Antigens, Ly | 1 | 2026 | 44 | 0.240 |
Why?
|
| Genetic Loci | 1 | 2026 | 116 | 0.230 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2025 | 16 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2026 | 61 | 0.230 |
Why?
|
| Interleukin-17 | 1 | 2026 | 99 | 0.230 |
Why?
|
| Crohn Disease | 1 | 2026 | 110 | 0.210 |
Why?
|
| Antigens, CD34 | 1 | 2024 | 53 | 0.210 |
Why?
|
| Genome-Wide Association Study | 1 | 2026 | 361 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2026 | 344 | 0.210 |
Why?
|
| Virus Latency | 1 | 2023 | 31 | 0.210 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1572 | 0.200 |
Why?
|
| Monocytes | 3 | 2022 | 362 | 0.200 |
Why?
|
| Antigens | 2 | 2014 | 145 | 0.200 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 182 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2024 | 150 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2025 | 2285 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 734 | 0.180 |
Why?
|
| Antigen Presentation | 2 | 2014 | 241 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 309 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2022 | 39 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2024 | 197 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2026 | 510 | 0.180 |
Why?
|
| Collagenases | 1 | 2021 | 16 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2022 | 120 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 171 | 0.170 |
Why?
|
| Time | 1 | 2021 | 29 | 0.170 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 239 | 0.170 |
Why?
|
| Doxycycline | 1 | 2021 | 47 | 0.170 |
Why?
|
| beta-Glucans | 1 | 2021 | 57 | 0.170 |
Why?
|
| Candida albicans | 1 | 2021 | 75 | 0.170 |
Why?
|
| Macrophages, Alveolar | 1 | 2021 | 67 | 0.170 |
Why?
|
| Sirtuin 3 | 1 | 2021 | 11 | 0.170 |
Why?
|
| Tuberculosis, Ocular | 1 | 2020 | 1 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 130 | 0.170 |
Why?
|
| Histones | 2 | 2022 | 494 | 0.170 |
Why?
|
| Guinea Pigs | 1 | 2020 | 86 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 34 | 0.160 |
Why?
|
| Data Accuracy | 1 | 2020 | 31 | 0.160 |
Why?
|
| Resistin | 1 | 2019 | 7 | 0.160 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2019 | 27 | 0.150 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 182 | 0.150 |
Why?
|
| Liver | 1 | 2024 | 867 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 218 | 0.150 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2019 | 5 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 326 | 0.150 |
Why?
|
| Autoimmunity | 1 | 2020 | 247 | 0.140 |
Why?
|
| HIV-1 | 1 | 2023 | 705 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 564 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 147 | 0.140 |
Why?
|
| Sirtuins | 1 | 2018 | 26 | 0.140 |
Why?
|
| Glycolysis | 1 | 2018 | 58 | 0.140 |
Why?
|
| Lysine | 1 | 2018 | 94 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 66 | 0.130 |
Why?
|
| Lung | 3 | 2026 | 966 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 225 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1040 | 0.130 |
Why?
|
| Phenotype | 1 | 2021 | 1232 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 279 | 0.130 |
Why?
|
| Mitochondria | 1 | 2021 | 400 | 0.130 |
Why?
|
| Immunity | 1 | 2017 | 108 | 0.130 |
Why?
|
| HIV Infections | 1 | 2023 | 955 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2022 | 793 | 0.120 |
Why?
|
| Polycarboxylate Cement | 1 | 2016 | 4 | 0.120 |
Why?
|
| Mycobacterium marinum | 2 | 2026 | 2 | 0.120 |
Why?
|
| Mannose | 1 | 2016 | 22 | 0.120 |
Why?
|
| Homeostasis | 1 | 2019 | 378 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2697 | 0.120 |
Why?
|
| Nitroreductases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 4 | 0.120 |
Why?
|
| Nanotechnology | 2 | 2014 | 139 | 0.110 |
Why?
|
| Interleukin-4 | 2 | 2012 | 147 | 0.110 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 127 | 0.110 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2014 | 7 | 0.110 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2014 | 7 | 0.110 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2014 | 5 | 0.110 |
Why?
|
| Male | 7 | 2026 | 30898 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1290 | 0.110 |
Why?
|
| Female | 7 | 2026 | 33857 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 151 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 160 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 208 | 0.100 |
Why?
|
| Riboflavin | 1 | 2013 | 18 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 172 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 112 | 0.100 |
Why?
|
| Computational Biology | 1 | 2015 | 366 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2013 | 10 | 0.100 |
Why?
|
| Microfluidics | 1 | 2013 | 25 | 0.100 |
Why?
|
| Zebrafish | 2 | 2026 | 369 | 0.090 |
Why?
|
| Peroxisomes | 1 | 2012 | 10 | 0.090 |
Why?
|
| Thymocytes | 1 | 2012 | 23 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 30 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2026 | 325 | 0.090 |
Why?
|
| Interferon-beta | 1 | 2011 | 79 | 0.090 |
Why?
|
| Rats, Wistar | 1 | 2011 | 182 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2011 | 102 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2026 | 3472 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2011 | 260 | 0.080 |
Why?
|
| Thymus Gland | 1 | 2012 | 239 | 0.080 |
Why?
|
| Obesity | 1 | 2019 | 1263 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2011 | 171 | 0.080 |
Why?
|
| Phagocytosis | 2 | 2024 | 268 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2024 | 373 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 116 | 0.080 |
Why?
|
| Acetylation | 2 | 2022 | 121 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 897 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 744 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 327 | 0.080 |
Why?
|
| Adult | 5 | 2026 | 17284 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 1996 | 0.070 |
Why?
|
| Chromatin | 2 | 2023 | 641 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 636 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 405 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2026 | 16 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2026 | 61 | 0.060 |
Why?
|
| United States | 1 | 2019 | 8067 | 0.060 |
Why?
|
| Candida | 1 | 2025 | 39 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2025 | 54 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2026 | 2153 | 0.060 |
Why?
|
| Virulence | 1 | 2025 | 201 | 0.060 |
Why?
|
| Oceania | 1 | 2025 | 2 | 0.060 |
Why?
|
| Global Burden of Disease | 1 | 2025 | 13 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 25 | 0.060 |
Why?
|
| Mycobacterium smegmatis | 1 | 2025 | 72 | 0.060 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2024 | 10 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2024 | 73 | 0.050 |
Why?
|
| Streptozocin | 1 | 2023 | 23 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2026 | 574 | 0.050 |
Why?
|
| Glycerol | 1 | 2023 | 34 | 0.050 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2025 | 92 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2024 | 518 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 526 | 0.050 |
Why?
|
| Homoserine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Middle Aged | 3 | 2026 | 18169 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 299 | 0.050 |
Why?
|
| Singapore | 1 | 2022 | 10 | 0.050 |
Why?
|
| South Africa | 1 | 2022 | 15 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2022 | 23 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 323 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 81 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2022 | 71 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 39 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2024 | 3150 | 0.040 |
Why?
|
| Microorganisms, Genetically-Modified | 1 | 2021 | 2 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2023 | 236 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 194 | 0.040 |
Why?
|
| CD11 Antigens | 1 | 2021 | 16 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2022 | 81 | 0.040 |
Why?
|
| Heme | 1 | 2021 | 30 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 91 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 168 | 0.040 |
Why?
|
| Serogroup | 1 | 2021 | 35 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 352 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 187 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 139 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2021 | 52 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 1413 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 41 | 0.040 |
Why?
|
| Cell Wall | 1 | 2021 | 120 | 0.040 |
Why?
|
| Dengue | 1 | 2021 | 96 | 0.040 |
Why?
|
| Melanoma | 1 | 2024 | 332 | 0.040 |
Why?
|
| Dengue Virus | 1 | 2021 | 99 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1437 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2021 | 221 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2021 | 146 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 180 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2026 | 829 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 740 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2023 | 907 | 0.040 |
Why?
|
| Cell Line | 1 | 2023 | 2036 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 17 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 80 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 752 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2021 | 351 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 72 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 181 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 98 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 396 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 4784 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 247 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 180 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 215 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1276 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2019 | 301 | 0.030 |
Why?
|
| Adipocytes | 1 | 2019 | 273 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 1634 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 687 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 299 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2022 | 1385 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 21 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1472 | 0.030 |
Why?
|
| Hemolysis | 1 | 2016 | 41 | 0.030 |
Why?
|
| Polymerization | 1 | 2016 | 36 | 0.030 |
Why?
|
| Cations | 1 | 2016 | 64 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2019 | 413 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2609 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 695 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 89 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2190 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1642 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Estrogens | 1 | 2015 | 116 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 95 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 260 | 0.030 |
Why?
|
| Microtechnology | 1 | 2014 | 6 | 0.030 |
Why?
|
| Mammals | 1 | 2016 | 223 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 198 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2014 | 31 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 92 | 0.030 |
Why?
|
| Polymers | 1 | 2016 | 332 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 19 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2012 | 29 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2012 | 26 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 110 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 522 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 90 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2013 | 125 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1560 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 344 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 14872 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2659 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1216 | 0.020 |
Why?
|